Cargando…
Trifolium Flavonoids Overcome Gefitinib Resistance of Non-Small-Cell Lung Cancer Cell by Suppressing ERK and STAT3 Signaling Pathways
Gefitinib is a tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor) and represents the first-line treatment for EGFR mutation patients with NSCLC (non-small-cell lung cancer) therapeutics. However, NSCLC patients are inclined to develop acquired gefitinib drug resistance through nowa...
Autores principales: | Wu, Zhiqiang, Xu, Bin, Yu, Zhiyi, He, Qin, Hu, Zhuyuan, Zhou, Shishi, Chen, Meiqin, Zhu, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603574/ https://www.ncbi.nlm.nih.gov/pubmed/33150167 http://dx.doi.org/10.1155/2020/2491304 |
Ejemplares similares
-
Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
por: Liu, Zhe, et al.
Publicado: (2021) -
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
por: Zhang, Yi, et al.
Publicado: (2015) -
EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC
por: Meng, Jiao, et al.
Publicado: (2019) -
ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells
por: Qi, Mengfan, et al.
Publicado: (2018) -
Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
por: Yeung, Yiu To, et al.
Publicado: (2018)